A 12-week study that evaluated the effect of treatment with rosiglitazone or metformin on top of glimepiride on inflammatory biomarkers in patients with T2DM demonstrated a 40% reduction in serum CRP levels at Week 12; a similar magnitude of change was reported for IL-6 and resistin. The gene discussed is RETN; the disease is type 2 diabetes mellitus.